HC Wainwright Predicts Higher Earnings for LENZ Therapeutics

Key Points

• HC Wainwright has increased its Q3 2025 earnings per share (EPS) estimate for LENZ Therapeutics from ($0.82) to ($0.67), while maintaining a "Buy" rating with a target price of $48.00.
• Other analysts have also raised their price targets, with Piper Sandler setting a price target of $51.00 and Citigroup increasing theirs to $49.00, reflecting strong confidence in the company's performance.
• LENZ Therapeutics reported a revenue of $5 million last quarter, exceeding estimates, and has a market capitalization of approximately $854.46 million.

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research note issued to investors on Thursday, July 31st. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.67) per share for the quarter, up from their prior forecast of ($0.82). HC Wainwright currently has a "Buy" rating and a $48.00 target price on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($2.76) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at $0.97 EPS and FY2029 earnings at $2.11 EPS.

Several other equities analysts have also commented on LENZ. Citigroup reaffirmed a "buy" rating and set a $49.00 target price (up previously from $45.00) on shares of LENZ Therapeutics in a report on Thursday, July 31st. Raymond James Financial raised their price objective on LENZ Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. Finally, Piper Sandler began coverage on shares of LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $49.60.

LENZ Therapeutics Trading Up 3.2%

Shares of LENZ stock traded up $0.96 during trading on Monday, hitting $31.13. The company's stock had a trading volume of 299,349 shares, compared to its average volume of 253,060. The business has a fifty day moving average of $31.10 and a 200-day moving average of $27.10. LENZ Therapeutics has a 52 week low of $16.53 and a 52 week high of $38.93. The company has a market cap of $887.83 million, a PE ratio of -16.38 and a beta of 0.42.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.05. The company had revenue of $5.00 million for the quarter, compared to the consensus estimate of $5.00 million.

Hedge Funds Weigh In On LENZ Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new position in shares of LENZ Therapeutics in the 4th quarter valued at about $46,000. Tower Research Capital LLC TRC increased its stake in LENZ Therapeutics by 162.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in shares of LENZ Therapeutics during the 4th quarter worth approximately $67,000. Banque Transatlantique SA bought a new stake in LENZ Therapeutics during the first quarter worth $119,000. Finally, GAMMA Investing LLC boosted its holdings in shares of LENZ Therapeutics by 5,254.1% during the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock worth $150,000 after buying an additional 5,727 shares during the period. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.